These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24864619)

  • 21. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
    Spellman CW
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S7-15. PubMed ID: 22267302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
    Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
    Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical decisions. Management of type 2 diabetes.
    Goldberg RB; Holman R; Drucker DJ
    N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
    [No Abstract]   [Full Text] [Related]  

  • 30. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weight beneficial treatments for type 2 diabetes.
    Meneghini LF; Orozco-Beltran D; Khunti K; Caputo S; Damçi T; Liebl A; Ross SA
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3337-53. PubMed ID: 21900381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin treatment for type 2 diabetes: when to start, which to use.
    Hamaty M
    Cleve Clin J Med; 2011 May; 78(5):332-42. PubMed ID: 21536829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes.
    van der Klauw MM; Wolffenbuttel BH
    Neth J Med; 2012 Dec; 70(10):436-43. PubMed ID: 23230012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes.
    Bloomgarden ZT; Blonde L; Garber AJ; Wysham CH
    Endocr Pract; 2012; 18 Suppl 3():6-26; quiz 27-8. PubMed ID: 23315305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.